Table 2.
Initial treatment response and site of disease progression.
| Variables | All Patients | Gefitinib | Erlotinib | Afatinib | Osimertinib | p-Value |
|---|---|---|---|---|---|---|
| Initial treatment response | ||||||
| Progressive disease (PD) | 18 (10%) | 4 (15%) | 9 (9%) | 5 (10%) | 0 (0%) | 0.6378 |
| Stable disease (SD) | 26 (14%) | 6 (22%) | 16 (15%) | 4 (8%) | 0 (0%) | |
| Partial response (PR) | 139 (75%) | 17 (63%) | 77 (74%) | 38 (79%) | 7 (100%) | |
| Complete response (CR) | 3 (2%) | 0 (0%) | 2 (2%) | 1 (2%) | 0 (0%) | |
| Disease control rate | 168 (90%) | 23 (85%) | 95 (91%) | 43 (90%) | 7 (100%) | 0.6325 |
| Response rate | 142 (76%) | 17 (63%) | 79 (76%) | 39 (81%) | 7 (100%) | 0.1390 |
| Initial intracranial treatment response † | ||||||
| Intracranial progressive disease (iPD) | 9 (6%) | 1 (5%) | 3 (3%) | 5 (11%) | 0 (0%) | 0.6033 |
| Intracranial stable disease (iSD) | 28 (18%) | 4 (20%) | 19 (22%) | 4 (9%) | 1 (14%) | |
| Intracranial partial response (iPR) | 76 (48%) | 9 (45%) | 43 (49%) | 20 (45%) | 4 (57%) | |
| Intracranial complete response (iCR) | 46 (29%) | 6 (30%) | 23 (26%) | 15 (34%) | 2 (29%) | |
| Intracranial disease control rate | 150 (94%) | 19 (95%) | 85 (97%) | 39 (89%) | 7 (100%) | 0.2667 |
| Intracranial response rate | 122 (77%) | 15 (75%) | 66 (75%) | 35 (80%) | 6 (86%) | 0.8749 |
| Site of disease progression | ||||||
| Intracranial progression | 48 (26%) | 5 (19%) | 24 (23%) | 19 (40%) | 0 (0%) | 0.0394 |
| Extracranial progression | 21 (11%) | 5 (19%) | 10 (10%) | 6 (13%) | 0 (0%) | 0.4469 |
| Lung | 5 (3%) | 1 (4%) | 3 (3%) | 1 (2%) | 0 (0%) | 0.9439 |
| Pleural nodule/effusion | 7 (4%) | 3 (11%) | 2 (2%) | 2 (4%) | 0 (0%) | 0.1516 |
| Bone | 9 (5%) | 0 (0%) | 6 (6%) | 3 (6%) | 0 (0%) | 0.5455 |
| Liver | 2 (1%) | 0 (0%) | 1 (1%) | 1 (2%) | 0 (0%) | 0.8397 |
| Adrenal gland | 1 (1%) | 1 (4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.1155 |
| Other | 1 (1%) | 1 (4%) | 0 (0%) | 0 (0%) | 0 (0%) | 0.1155 |
† Initial intracranial treatment response was assessed in 159 patients. Data are presented as n (%). p-values are presented for the results of the chi-squared test.